Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of UI059 vs UIC202201 in Healthy Adults
NCT06141577Phase 1Completed
- Sponsor
- Korea United Pharm Inc.
- Start
- Oct 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of UI-059 in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Korea United Pharm Inc. Primary endpoints: Area Under the Concentration-Time Curve at Steady State over the Dosing Interval and Percent decrease from baseline in integrated gastric acidity at Day 7. Started Oct 2023; status: completed.
02
Drugs
UI-059
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT06141577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06141577.